Analyst Mike Kratky of Leerink Partners reiterated a Buy rating on NeuroPace (NPCE – Research Report), retaining the price target of $18.00.
Mike Kratky has given his Buy rating due to a combination of factors including NeuroPace’s strong financial performance and promising future prospects. The company’s fourth-quarter earnings were in line with expectations, showing robust sales and effective cost management. The recent momentum from Project CARE and a strengthened balance sheet further enhance the company’s financial stability, supporting the expectation that they will reach cash flow breakeven by the end of 2027.
Additionally, NeuroPace’s guidance for fiscal year 2025 indicates continued growth, with revenue projections surpassing consensus estimates. The anticipated results from the NAUTILUS study and FDA submissions are seen as potential catalysts for stock transformation. The company’s strategic initiatives, including the expansion of the RNS system and expected approvals for new patient groups, are expected to drive significant revenue growth, making the stock an attractive investment opportunity.
In another report released on March 5, Cantor Fitzgerald also maintained a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NPCE in relation to earlier this year.